Your browser doesn't support javascript.
loading
Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?
Raphael, J; Mazouni, C; Caron, O; Ferchiou, M; Delaloge, S.
Affiliation
  • Raphael J; Breast Cancer Group, Department of Medicine, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France, raphaeljack13@hotmail.com.
Med Oncol ; 31(3): 850, 2014 Mar.
Article in En | MEDLINE | ID: mdl-24448978
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Germ-Line Mutation / Carcinoma, Ductal, Breast / BRCA1 Protein / Neoadjuvant Therapy / BRCA2 Protein Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Germ-Line Mutation / Carcinoma, Ductal, Breast / BRCA1 Protein / Neoadjuvant Therapy / BRCA2 Protein Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Language: En Journal: Med Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication: